
==== Front
Int J Microbiol
Int J Microbiol
IJMICRO
International Journal of Microbiology
1687-918X
1687-9198
Wiley

10.1155/2024/9282571
Research Article
Prevalence, Antibiotic Susceptibility Pattern and Associated Factors of Streptococcus pyogenes among Pediatric Patients with Acute Pharyngitis in Sidama, Southern Ethiopia
https://orcid.org/0000-0001-9621-7850
Gebre Alemitu Beyene alemitubeyene5@gmail.com
1
https://orcid.org/0000-0003-3914-838X
Fenta Demissie Assegu 1
Negash Abel Abera 2
Hayile Betelihem Jima 1
1 Hawassa University College of Medicine and Health Science School of Medical Laboratory Science, Hawassa, Ethiopia
2 Armauer Hansen Research Institute, Addis Ababa, Ethiopia
Academic Editor: Rahul Shivahare

2024
17 9 2024
2024 92825717 9 2023
12 8 2024
4 9 2024
Copyright © 2024 Alemitu Beyene Gebre et al.
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background

Streptococcus pyogenes is the most frequent cause of pharyngitis and skin infections in children and causes immune complications like rheumatic fever and rheumatoid heart disease (RHD), particularly in developing countries like Ethiopia. The aim of this study was to determine the prevalence, antibiotic resistance pattern, and associated factors of Streptococcus pyogenes among pediatric patients suspected of acute pharyngitis in Sidama Region, Southern Ethiopia.

Methods

A cross-sectional study was conducted on 213 acute pharyngitis suspected pediatric patients from April to September 2022 at Hawassa University Compressive Specialized Hospital and Yirgalem Hospital. Sociodemographic and clinical data were collected using a structured questionnaire. A throat swab was cultured to isolate S. pyogenes, and antimicrobial susceptibility testing was done using standard bacteriological techniques. Data were analyzed using SPSS version 25, and P value of <0.05 was considered as statistically significant.

Result

Out of 213 throat swabs cultured, 22 (10.3%) with 95% CI (6.6–14.6%) were S. pyogenes positive. All isolates of S. pyogenes were sensitive to penicillin and amoxicillin. In contrast, 8 (36.4%) isolates exhibited resistance to tetracycline, 7 (31.8%) to ceftriaxone, 6 (27.3%) to erythromycin, and 5 (22.7%) isolates showed multidrug resistance. The presence of palatal petechiae (P=0.037) and tonsillar swelling or exudate (P=0.007) were significantly associated with S. pyogenes carriage in children suspected of having acute pharyngitis.

Conclusion

In this study, the prevalence of S. pyogenes among children suspected with acute pharyngitis was low compared to other studies. The isolates showed a high level of resistance to commonly used antibiotics. Therefore, the treatment of pediatric acute S. pyogenes pharyngitis should depend on an antimicrobial susceptibility test. Furthermore, evaluation of S. pyogenes pediatric acute pharyngitis risk factors and tracking of antibiotic resistance are crucial in the controlling of pediatric acute S. pyogenes pharyngitis.
==== Body
pmc1. Introduction

Streptococcus pyogenes (S. pyogenes) is a Gram-positive, facultative anaerobic, β-hemolytic bacterium classified as group A streptococcus based on carbohydrate it contains [1, 2]. It is the most frequent cause of skin and oropharyngeal infections, which can develop into more serious invasive and suppurative conditions like toxic shock syndrome and necrotizing fasciitis, which have been associated to increased rates of morbidity and mortality globally [3–5]. Of these infections, pharyngitis is the most common among children, particularly those between the ages of 5 and 14 years. It causes 288.6 million episodes, with a high episode rate of 40 per 100 child in the low- and middle-income countries (LMICs), translating into 0.1 million disability-adjusted living years (DALYs) yearly [6]. The frequency of S. pyogenes pharyngitis was highest in sub-Saharan Africa, with a rate of 5.7 per 1000, as compared to 1.8 per 1000 in North Africa and 0.3 per 1000 in developed nations [7]. For example, a 2017 study conducted in Uganda found that of 600 million cases of pharyngitis, 450 million cases were thought to be caused by S. pyogenes per year, with 20 to 40% of those cases being in children [8], despite, there are few publications of S. pyogenes in Africa [9].

S. pyogenes is a contagious organism and can spread through direct or indirect contact with respiratory tract secretions, wounds, or sores on infected people's skin [10]. The infection varies depending on a number of factors, including age, gender, and standard of living in addition to seasonal variations and indoor air pollution [11]. S. pyogenes remains susceptible to penicillin, and penicillin has proven to be an effective empirical treatment antibiotic for S. pyogenes infection. However, patients who have developed allergies to penicillin are treated with alternative antibiotics such as cephalosporin, lincosamides, and macrolides drugs [12, 13]. However, currently there have been varying reports of S. pyogenes resistance to cephalosporin, lincosamides, and macrolides (erythromycin and azithromycin) [4, 12, 14]. This antibiotic resistance of S. pyogenes is mainly associated with drug overuses and poststreptococcus infection complication such as glomerulonephritis, rheumatic fever (RF), and rheumatic heart disease (RHD) which is the main concern worldwide [15, 16].

In Ethiopia, data regarding S. pyogenes in children suspected with pharyngitis and antibiotic resistance are extremely limited, especially in the study area. The earlier study conducted in the study area found that 12% of children had asymptomatic pharyngeal carriage of S. pyogenes [17]. This was somewhat higher than the 9.1–11.3% prevalence of S. pyogenes among children in other regions who were suspected of having pharyngitis [17–19] and demand great attention. Additionally, both nationally and in the study area, empirical medications are the mainstay of treatment for S. pyogenes pharyngitis in Ethiopia. Despite S. pyogenes pharyngitis infection's high resistance to clindamycin, ceftriaxone, cefotaxime, cefepime, and erythromycin, antibiotics are prevalent in Ethiopia [18]. Also, tetracycline and azithromycin resistance was highly observed in both asymptomatic and symptomatic S. pyogenes pharyngitis infections [17, 19, 20] in addition to multidrug resistant (MDR) cases [18]. Therefore, the aim of this study was to determine the prevalence of S. pyogenes, antibiotic susceptibility pattern, and associated factors among children suspected with acute pharyngitis in Sidama, Southern Ethiopia.

2. Materials and Methods

2.1. Study Area, Design, and Period

A hospital-based cross-sectional study was conducted at two government hospitals: Hawassa University Comprehensive Specialized Hospital (HUCSH) and Yirgalem General Hospital, in Sidama region, Southern Ethiopia, from April 15 to September 10, 2022. Hawassa University Comprehensive Specialized Hospital (HUCSH) is located at Hawassa City which is 275 km from Addis Ababa, the capital city of Ethiopia. It is the only comprehensive specialized hospital in Southern Ethiopia and provides different health services for more than 18 million peoples in Sidama region, Southern Nations, Nationalities, and Peoples (SNNPR), Southern Oromia, and some part of Somalia regions. Similarly, Yirgalem General Hospital which is located 322 km from Addis Ababa and 47 km from Hawassa City, the second largest hospital in Sidama region gives different health services in the catchment area and the community from surrounding.

2.2. Study Population

All pediatric patients who were attending pediatric emergency wards in both hospitals during the study period were the study population.

2.3. Inclusion and Exclusion Criteria

All children under 18 years of age with symptoms of acute pharyngitis whose parents accepted the consent were included in this study; however, children who have been on antibiotics in the last two weeks were excluded from the study [18].

2.4. Sample Size Determination and Sampling Techniques

Sample size was determined using the following assumptions: 95% confidence interval (CI), power of 80%, and previous odds ratio of associated factors from Bahir Dar [18], by using EPI INFO stat calc version 7 software. To minimize errors arising from the likelihood of noncompliance, 10% of the sample size was added. Finally, by considering the 10% nonresponse rate, the sample size calculated was 213. A systematic random sampling technique was applied to select 213 respondents for interview.

2.5. Sampling Procedure and Sampling Technique

The participant's proportional allocation was calculated based on previous child flow data due to acute pharyngitis per month from each hospital's logbook. A systematic random sampling technique was applied to select 213 children who were suspected of having acute pharyngitis: 142 from HUCSH and 71 from Yirgalem General Hospital. To choose the first participant, the K interval was calculated. After the K interval was calculated, the first individual was selected by the lottery method and the others at a regular interval.

2.6. Operational Definition

Multidrug resistance (MDR): a species of microorganisms that is resistant to at least one agent in ≥3 antimicrobial categories [21].

Acute pharyngitis: a clinical feature characterized by sudden onset of sore throat, palatal petechiae, anterior cervical lymphadenopathy, and tonsillar swelling with or without exudates [22].

2.7. Collection of Sociodemographic and Clinical Data

Sociodemographic characteristics data from the parents or children, as well as the children's clinical history, were collected by trained nurses using a structured questionnaire under physician supervision during children acute pharyngitis clinical examination.

2.8. Sample Collection and Transportation Methods

Two throat samples were collected by trained nurses, one for Gram staining and the other for culture purpose, by using a sterile cotton swab and a sterile disposable tongue depressor from each child under physician supervision. Each collected swab was immediately immersed in the Amies transport medium (Oxoid, England). Samples were then transported to the Hawassa University School of Medical Laboratory, Microbiology laboratory within half an hour at room temperature from the Hawassa University Comprehensive Specialized Hospital, and using a cold bag from Yirgalem General Hospital.

2.9. Streptococcus pyogenes Identification

The throat swab was inoculated on blood agar plates (blood agar base Oxoid UK) by rolling the swab over a small area of the plate and streaking the sample using a sterile loop. The plates were then incubated for 24 hours at 37°C in a candle jar, which can provide an atmosphere of 5% CO2. A plate culture that was negative for beta-hemolytic colonies after 24 hours was incubated for an additional 24 hours to allow the growth of slow growers. Beta-hemolytic streptococci were checked by their colony morphology, beta-hemolysis, and gram stain. Gram-positive and catalase-negative streptococcus bacteria were confirmed by bacitracin disc sensitivity and pyrolidonyl arylamidase (PYR) tests. Bacitracin-sensitive and a purple color in PYR tests were identified as S. pyogenes [23].

2.10. Antimicrobial Susceptibility Testing

An antimicrobial susceptibility test was performed by the disc diffusion method using Mueller–Hinton agar (MHA) (Oxoid UK) supplemented with 5% sheep blood according to the Clinical Laboratory Standards Institute (CLSI) 2021 guidelines [24]. Colony suspension was made using normal saline (0.85% NaCl) equivalent to 0.5% McFarland standard from colonies grown for 24 hrs on a sheep blood agar plate. The suspension was inoculated on the MHA plate with 5% sheep blood using a culture swab and incubated at 5% CO2 for 24 hours. Based on the CLSI 2021 guideline, ceftriaxone (30 μg), cefepime (30 μg), clindamycin (2 μg), erythromycin (15 μg), penicillin (10 IU), amoxicillin (10 µg), chloramphenicol (30 µg), and tetracycline (30 μg) antibiotic-impregnated disks (Abteck Biologicals Ltd) were selected. Finally, the zone of inhibition was measured with a ruler and interpreted according to the CLSI 2021 guideline value.

2.11. Statistical Analysis

Data were entered into Epi Info version 3.1 and analyzed using SPSS version 25. S. pyogenes prevalence, variable frequency, and antimicrobial susceptibility pattern were determined by descriptive statistics. Bivariate logistic regression analysis was used to determine the associated risk factors. For those variables which have a P value <0.25 in the bivariate, the analysis was further entered into the multivariable logistic regression model and a P value of <0.05 was considered statistically significant at 95% CI.

2.12. Data Quality Control

Prior to actual data collection, the quality of the data was assured by pretesting 5% of questionnaires at Adare General Hospital, Hawassa City. Training was given to the data collector's physician and nurses. For the laboratory test, the sterility of prepared culture media was checked by incubating the 5% of prepared media in a 5% CO2-enriched atmosphere at 37°C for 24 hours. For each test, a quality control strain of S. pyogenes (ATCC19615) from the Ethiopian Public Health Institute (EPHI) was used as the positive control to check all media, biochemical tests, and antibiotics. To maintain the quality of the work and data management, the standard operating procedure for sample collection and laboratory analysis was strictly followed.

2.13. Ethical Approval and Consent to Participate

Ethical approval was obtained from the Institutional Review Board of Hawassa University, College of Medicine and Health Sciences (Ref. No: IRB/010/14). Permission was obtained from the clinical and academic director of HUCSH and Yirgalem General Hospital. Before enrolling, any of the eligible study participants' written informed consent was obtained from the children's parents or caregivers, and assent was also obtained from minors. Finally, all procedures were conducted based on the ethical Declaration of Helsinki guidelines, and all information was kept confidential. All positive results were reported to the Pediatrics Emergency Department of HUCSH and Yirgalem General Hospital physicians for appropriate antibiotic treatment.

3. Results

3.1. Sociodemographic Characteristics of Study Participants

This study included 213 children who were suspected of having acute pharyngitis. Among the children included in this study, 114 (53.1%) were males. The mean age of the study participants was 5.7, with a standard deviation (SD) of ±3.22 years. Of the participants, 199 (93.4%) were from urban areas. Regarding clinical characteristics, out of the 213 children, 138 (64.8%), 17 (8.0%), and 25 (11.7%) had a history of tonsillitis, otitis media, and conjunctive, respectively. Moreover, 138 (64.8%) of them had petechiae on the palate, 83 (39.0%) had enlarged anterior cervical lymph nodes, and 90 (42.3%) had tonsillar swelling or exudate (Table 1).

The overall prevalence of S. pyogenes was 22 (10.3%) and was more predominant in males, 17 (8.0%) than females. S. pyogenes acute pharyngitis was 12 (5.6%) more prevalent in children aged <5 years. Among the children with culture proven S. pyogenes pharyngitis, 15 (7.0%) of their parents were working in private occupations. Furthermore, S. pyogenes pharyngitis was more prevalent among children with a previous history of tonsil, 15 (7.0%), and tonsillar swelling or exudate, 14 (6.6) (Table 1).

3.2. Antimicrobial Susceptibility Testing Patterns

All S. pyogenes isolates were sensitive to both penicillin and amoxicillin. The highest rate of drug resistance was observed for tetracycline, 36.4% (8/22) followed by ceftriaxone, 31.8% (7/22), and erythromycin, 27.3% (6/22) (Figure 1).

Overall, in this study, 5/22 (22.7%) of the S. pyogenes isolates showed multidrug resistance (MDR). Of those, 1 (4.5%) exhibited resistance to erythromycin, ceftriaxone, and tetracycline and about 1 (4.5%) was resistant to clindamycin, azithromycin, and tetracycline, while the other 1 (4.5%) demonstrated resistance to ceftriaxone, chloramphenicol, erythromycin, and tetracycline. Additionally, the left two individuals (9.1%) exhibited resistance to erythromycin, ceftriaxone, cefepime, and tetracycline (Table 2).

3.3. Factors Associated with S. pyogenes Pharyngitis

In bivariate analysis, sex, age, parent occupation, number of windows, tonsillar swelling or exudate, nasal flow, and vomiting were found to be statistically significant at a P value of <0.25 and were therefore taken into consideration as potential candidates for multivariate analysis. After adjusting other confounding variables, boys' children were 3.91 times more likely to develop S. pyogenes acute pharyngitis than girls' children (AOR = 3.91; 95% CI = 1.297–11.792; P=0.015), children with palatal petechiae were 65% more likely to develop S. pyogenes acute pharyngitis than without (AOR = 0.35; 95% CI = 0.131–0.938; P=0.037), and children with tonsillar swelling or exudate were 3.83 times more likely to develop S. pyogenes acute pharyngitis than those who have not developed tonsillar swelling or exudate (AOR = 3.83; 95% CI = 1.446–10.188, P=0.007) (Tables 3 and 4).

4. Discussion

S. pyogenes, the most common cause of acute pharyngitis infections, causes an annual incidence of over 600 million and is associated with morbidity and mortality worldwide [4]. In this study, the overall prevalence of S. pyogenes was 22 (10.3%), with 95% CI (6.6–14.2%). This finding was comparable with the Ethiopian previous studies' result of different areas, Jimma, 11.3% [19], Gondar, 10.7% [20], Bahir Dar, 9.1% [18], and another country, Indonesia, 7.9% [25]. However, our finding was higher than studies reported from Thailand 6.5% [26] and India 5.5% [27]. In contrast, the finding was lower than studies conducted in Nigeria 15.3% [28], Sudan, 25.5% [1], 15.1% Zambia [22], 30% Iran [29], 34.1% Japan [30], and 41.5% Aden Yemen [31]. This difference may be due to the geographical area, socioeconomic conditions, seasonal variations, indoor air pollution, vaccination status, study design, sample size, and sampling technique [11, 32].

In this study, all S. pyogenes isolates were sensitive to penicillin. This result was consistent with previous studies reported from different parts of Ethiopia [18–20] and studies from China [3], Iran [29], Israel [13], Zambia [22], and Thailand [26]. In addition, the current study revealed that S. pyogenes was 100% sensitive to amoxicillin, which was similar to a previous study in Jimma, Ethiopia, that reported S. pyogenes 100% sensitivity to amoxicillin [19]. In contrast, a study conducted in Sudan reported that 58.8% of the isolates were resistant to amoxicillin [1]. Majority of the S. pyogenes isolates in the current study were also susceptible to the actions of azithromycin (86.4%), cefepime (90.9%), and clindamycin (95.5%). This result was higher than those study's results reported from Bahir Dar, Northern Ethiopia [18], and Gondar, Northwest Ethiopia [20].

The relatively higher level of resistance in the study from Bahir Dar may be due to a difference in the level of antibiotic use in Bahir Dar [18] and Gondar [20] studies.

In the contrast, the isolates demonstrated resistance of 36.4%, 31.8%, and 27.3% to tetracycline, ceftriaxone, and erythromycin, respectively. Similarly, S. pyogenes was found to be resistant to those antibiotics in other studies. The current tetracycline finding was greater than studies conducted in Gondar, Northwest Ethiopia, 21.7% [20], and Bahir Dar, Northern Ethiopia, 14.3% [18], but lower than Jimma, Southwest Ethiopia, 52.5% [19]. Additionally, the rate of erythromycin resistance is higher than in previous studies conducted in Ethiopia, Jimma [19], no resistance, Gondar 4.3% [20], and Bahir Dar 21.4% [18], and other countries like India with no resistance [27], Thailand 18.2% [26], but less than the finding from Iran 37.2% [29]. Similarly, the finding of ceftriaxone resistance was greater than a study conducted in Gondor, Ethiopia, 13% [18], but lower than a study in Thailand with no resistance [27]. Furthermore, 22.7% of the S. pyogenes isolates in this study were found to be multidrug resistant (MDR), which was marginally higher than the 21.3% found in a previous study conducted in Bahir Dar, Northern Ethiopia [18]. The observed variations in antibiotic sensitivity and phenotypic multidrug resistance in S. pyogenes could potentially be attributed to noncompliance with medication regimens or excessive drug consumption within the study area, as well as empirical pharyngitis treatment practices [33]. Furthermore, the primary emergence of MDR secondary to drug resistance is maybe due to beta-lactamase enzyme production, which carries genes specific to drug resistance, modifies antimicrobial targets, and activates the drug efflux pump of S. pyogenes [2, 12].

According to the associated factors, in the current study, boys were 3.91 times more likely than females to experience S. pyogenes acute pharyngitis (P value = 0.015). This result is in line with other studies reported from Taiwan [34] and Japan [30] which revealed that S. pyogenes pharyngitis is more associated with boys than girls. Similarly, the review studies conducted in China [35, 36] and United States [37, 38] also stated that S. pyogenes infection was more prevalent in boys than in girls. However, this result was at odds with previous Ethiopian studies carried out in Jimma [19], Gojam [20], and Bahir Dar [18] which, despite being statistically not significant, reported a higher prevalence of S. pyogenes pharyngitis in boys than in girls. This difference may be due to variations in study subjects, living standards, parental occupation, seasonal variations, and immune status between males and females [11, 39]. Concerning clinical factors, the presence of palatal petechiae and tonsillar swelling or exudate was significantly associated to children with S. pyogenes acute pharyngitis with P values of 0.037 and 0.007, respectively. This finding was in agreement with the previous studies of Jimma, Southwest Ethiopia [19], and Gondar, Northwest Ethiopia [20], and the other study from the United States of America [40]. However, our finding was in contradiction with the study from California [41] that stated a patient with no palatal petechiae clinical symptom was positive for S. pyogenes. In fact, palate petechiae and swollen tonsils or exudate were the most prevalent symptoms of S. pyogenes pharyngitis with sudden onset of fever and sore throat [29, 42, 43]. However, the geographical location and study subjects have an impact on the clinical characteristics of S. pyogenes pharyngitis [32].

4.1. Limitations of the Study

We acknowledge that there are some limitations in the study. The limitation of this study is its small size and small number of study sites which may underestimate the prevalence of S. pyogenes. Moreover, we did not perform the minimum inhibitory concentration (MIC) antimicrobial susceptibility test method rather than disc diffusion.

5. Conclusion

The prevalence of S. pyogenes, 10.3% in this study, was low compared to other studies. Penicillin and amoxicillin are effective drugs for the treatment of pediatric acute pharyngitis caused by S. pyogenes. Clindamycin and cefepime prescriptions are more suggested for case penicillin allergies materialize. Nevertheless, a significant rate of S. pyogenes resistance was noted to erythromycin, ceftriaxone, and tetracycline, which were the routine treatments for pediatric acute pharyngitis. Being boys is more susceptible to S. pyogenes acute pharyngitis than being girls. Palatal petechiae and tonsillar swelling or exudate are the clinical predictors for S. pyogenes acute pharyngitis. Therefore, the treatment of S. pyogenes acute pharyngitis among children should be depending on antimicrobial susceptibility patterns. Moreover, continued surveillance of S. pyogenes prevalence, antibiotic resistance, and risk factors is very important in controlling S. pyogenes pediatric acute pharyngitis. Developing specific guidelines for S. pyogenes and strengthening of laboratory infrastructure are significant to minimize the empirical treatment of S. pyogenes pediatric acute pharyngitis in Ethiopia.

Acknowledgments

We would like to thank all participants' parents for their kind voluntary permission to participate their children in this study. Furthermore, Hawassa University and Hawassa University School of Medical Laboratory Science and Yirgalem General Hospital staff for their logistic support.

Abbreviations

HUCSH: Hawassa University comprehensive specialized hospital

IRB: Institutional review board

SNNPR: Southern nations, nationalities, and peoples region.

Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare that they have no any conflicts of interest in this work.

Authors' Contributions

ABG performed conceptualization and design of the study, investigation, analysis and interpretation of data, writing of the original draft, project administration, and final version approval. DAF conducted analysis and interpretation of data, project administration, visualization, writing, reviewing, and editing, and final version approval. AAN collected materials, performed analysis and interpretation of data, writing, reviewing, and editing, and final version approval. BJH performed analysis and interpretation of data, visualization, writing, reviewing, and editing.

Figure 1 Antibiotic susceptibility pattern of S. pyogenes among pediatric patients with acute pharyngitis at HUCSH and Yirgalem General Hospital, 2022.

Table 1 Prevalence of S. pyogenes with respect to sociodemographic and clinical characteristics of pediatric patients with acute pharyngitis at HUCSH and Yirgalem General Hospital, 2022.

Sociodemographic variables	Categories	Culture result for S. pyogenes (n/213)	Frequency	(%)	
Positive n (%)	Negative n (%)	
Sex	Male	17 (8.0)	97 (45.5)	114	53.5	
Female	5 (2.3)	94 (44.1)	99	46.5	
	
Age	<5 years old	12 (5.6)	83 (39.0)	95	44.6	
5–9 years old	9 (4.2)	83 (39.0)	92	43.2	
≥10 years old	1 (0.5)	25 (11.7)	26	12.2	
	
Residence	Rural	0 (0)	14 (6.6)	14	6.6	
Urban	22 (10.3)	177 (83.1)	199	93.4	
	
Children education level	Preschool	9 (4.2)	77 (36.2)	86	40.4	
Kindergarten	9 (4.2)	72 (33.8)	81	38.0	
Grade 1–4	4 (1.9)	42 (19.7)	46	21.6	
	
Children living status	Mother and father	21 (9.9)	186 (87.3)	207	97.2	
Mother only	1 (0.5)	5 (2.3)	6	2.8	
	
Family size	<5	12 (5.6)	124 (58.2)	136	63.8	
≥5	10 (4.7)	67 (31.5)	77	36.2	
	
Parent educational level	No formal education	2 (0.9)	15 (7.0)	17	8.0	
Elementary	2 (0.9)	36 (16.9)	38	17.8	
High school	8 (3.8)	65 (30.5)	73	34.3	
Diploma and above	10 (4.7)	75 (35.2)	85	39.9	
	
Parent occupational status	Government	2 (0.9)	39 (18.3)	41	19.2	
Private	15 (7.0)	123 (57.7)	138	64.8	
Farmer	1 (0.5)	10 (5.2)	11	5.2	
House worker	4 (1.9)	19 (8.9)	23	10.8	
	
Non separated living room and kitchen	Yes	5 (2.3)	41 (19.2)	46	21.6	
No	17 (8.0)	150 (70.4)	167	78.4	
	
Number of windows in the house	1	2 (0.9)	36 (16.9)	38	17.8	
2	13 (6.1)	82 (38.5)	95	44.6	
≥3	7 (3.3)	73 (34.3)	80	37.6	
	
Clinical variables	
Vaccine complete	Yes	19 (8.9)	162 (76.1)	181	85.0	
No	3 (1.4)	29 (13.6)	32	15.0	
	
Previous history of tonsillitis	Yes	15 (7.0)	122 (57.3)	138	64.8	
No	7 (3.3)	69 (32.4)	75	35.1	
	
Previous otitis media	Yes	3 (1.4)	27 (12.7)	17	8.0	
No	19 (8.9)	164 (77.0)	196	92.0	
	
Previous conjunctivitis	Yes	3 (1.4)	22 (10.3)	25	11.7	
No	19 (8.9)	169 (79.3)	188	88.3	
	
Enlarged anterior cervical lymph node	Yes	8 (3.8)	75 (35.2)	83	39.0	
No	14 (6.6)	116 (54.5)	130	61.0	
	
Palatal petechial	Yes	10 (4.7)	128 (60.1)	138	64.8	
No	12 (5.6)	63 (29.6)	75	35.2	
	
Tonsillar swelling or exudate	Yes	14 (6.6)	76 (35.7)	90	42.3	
No	8 (3.8)	115 (54.0)	123	57.7	
	
Cough	Yes	14 (6.6)	100 (46.9)	114	53.6	
No	8 (3.8)	91 (42.7)	99	46.5	
	
Fever	>3 days	13 (6.1)	92 (43.2)	105	49.3	
≤3 days	9 (4.2)	99 (46.5)	108	50.7	
	
Headache	Yes	6 (2.8)	48 (22.5)	54	25.4	
No	16 (7.5)	143 (67.1)	159	74.6	
	
Nasal flow	Yes	15 (7.0)	91 (42.7)	106	49.8	
No	7 (3.3)	100 (46.9)	107	50.2	
	
Abdominal pain	Yes	4 (1.9)	51 (23.9)	55	25.8	
No	18 (8.5)	140 (65.7)	158	74.2	
	
Vomiting	Yes	11 (5.2)	128 (60.1)	139	65.3	
No	11 (5.2)	63 (29.6)	74	34.7	

Table 2 Multiple drug resistant of S. pyogenes isolated from pediatric with acute pharyngitis at HUCSH and Yirgalem General Hospital, 2022.

Resistance of antibiotics	N (%)	MDR (n (%))	
Ceftriaxone	3 (13.6)	 	
Tetracycline	3 (13.6)	 	
Erythromycin	2 (9.1)	 	
Ceftriaxone, erythromycin, tetracycline	1 (4.5)	1 (4.5)	
Clindamycin, azithromycin, tetracycline	1 (4.5)	2 (9.1)	
Erythromycin, ceftriaxone, cefepime, tetracycline,	1 (4.5)	 	
Ceftriaxone, chloramphenicol, erythromycin, tetracycline	1 (4.5)	2 (9.1)	
Erythromycin, ceftriaxone, cefepime, tetracycline	1 (4.5)	 	
Key: MDR-Multidrug resistant.

Table 3 Bivariate and multivariable logistic regression analysis of factors associated with S. pyogenes acute pharyngitis at HUCSH and Yirgalem General Hospital, 2022.

Socio-demographic characteristics	Categories	Culture result for S. pyogenes (n/213)	COR (95% CI)	P value	AOR (95% CI)	P value	
Positive n (%)	Negative n (%)	
Sex	Male	17 (8.0)	97 (45.5)	3.29 (1.168–9.291)	0.024	3.91 (1.297–11.792)	0.015∗	
Female	5 (2.3)	94 (44.1)	1	 	1	 	
	
Age	<5 years	12 (5.6)	83 (39.0)	0.28 (0.034–2.233)	0.228	0.23 (0.027–1.972)	0.181	
5–9 years	9 (4.2)	83 (39.0)	0.37 (0.045–3.054)	0.355	0.25 (0.028–2.230)	0.215	
≥10 years	1 (0.5)	25 (11.7)	1	 	 	 	
	
Residence	Rural	0 (0)	14 (6.6)	—	—	 	 	
Urban	22 (10.3)	177 (83.1)	—	—	—	—	
	
Children education level	Preschool	9 (4.2)	77 (36.2)	0.82 (0.237–2.805)	0.745	—	—	
Kindergarten	9 (4.2)	72 (33.8)	0.76 (0.221–2.627)	0.667	—	—	
Grade 1–4	4 (1.9)	42 (19.7)	1	 	 	 	
	
Children living status	Mother and father	21 (9.9)	186 (87.3)	1.77 (0.197–15.890)	0.609	—	—	
Mother only	1 (0.5)	5 (2.3)	1	 	—	—	
	
Family size	<5	12 (5.6)	124 (58.2)	0.65 (0.266–1.579)	0.337	—	—	
≥5	10 (4.7)	67 (31.5)	1	 	—	—	
	
Parent educational level	No formal education	2 (0.9)	15 (7.0)	1	 	 	 	
Elementary	2 (0.9)	36 (16.9)	2.40 (0.309–18.651)	0.403	—	—	
High school	8 (3.8)	65 (30.5)	1.08 (0.208–5.630)	0.924	—	—	
Diploma and above	10 (4.7)	75 (35.2)	1.00 (0.199–5.034)	1.000	—	—	
	
Parent occupational status	Government	2 (0.9)	39 (18.3)	1	 	 	 	
Private	15 (7.0)	123 (57.7)	4.11 (0.690–24.435)	0.121	0.38 (0.079–1.808)	0.223	
Farmer	1 (0.5)	10 (5.2)	1.73 (0.518–5.755)	0.374	0.26 (0.015–4.587)	0.359	
House worker	4 (1.9)	19 (8.9)	2.11 (0.207–21.449)	0.530	0.21 (0.034–1.360)	0.102	
	
Nonseparated living room and kitchen	Yes	5 (2.3)	41 (19.2)	1	 	 	 	
No	17 (8.0)	150 (70.4)	1.08 (0.375–3.091)	0.892	—	—	
	
Number of windows in the house	1	2 (0.9)	36 (16.9)	1	 	1	 	
2	13 (6.1)	82 (38.5)	0.35 (0.075–1.634)	0.182	0.21 (0.034–1.303)	0.094	
≥3	7 (3.3)	73 (34.3)	0.58 (0.114–2.932)	0.509	0.42 (0.064–2.804)	0.372	
Key: AOR: adjusted odds ratio, COR: crude odds ratio, CI: confidence interval, Note.∗Indicates the significant relation between variables, P value <0.05.

Table 4 Bivariate and multivariable logistic regression analysis of the clinical factor with S. pyogenes acute pharyngitis at HUCSH and Yirgalem General Hospital, 2022.

Clinical factors	Categories	Culture result for S. pyogenes (n/213)	COR (95% CI)	P value	AOR (95% CI)	P value	
Positive n (%)	Negative n (%)	
Vaccination complete	Yes	19 (8.9)	162 (76.1)	0.88 (0.245–3.173)	0.848	—	—	
No	3 (1.4)	29 (13.6)	1	 	 	 	
	
Previous history of tonsil	Yes	15 (7.0)	122 (57.3)	0.82 (0.321–2.122)	0.690	—	—	
No	7 (3.3)	69 (32.4)	1	 	 	 	
	
Previous otitis media	Yes	3 (1.4)	27 (12.7)	1.00	 	—	—	
No	19 (8.9)	164 (77.0)	0.95 (0.266–3.463)	0.949	—	—	
	
Previous conjunctivitis	Yes	3 (1.4)	22 (10.3)	1	 	 	 	
No	19 (8.9)	169 (79.3)	1.21 (0.332–4.433)	0.770	—	—	
	
Enlarged anterior cervical lymph node	Yes	8 (3.8)	75 (35.2)	1	 	—	—	
No	14 (6.6)	116 (54.5)	0.88 (0.354–2.209)	0.791	—	—	
	
Palatal petechiae	Yes	10 (4.7)	128 (60.1)	1	 	1	 	
No	12 (5.6)	63 (29.6)	0.41 (0.168–1.001)	0.045∗	0.35 (0.131–0.938)	0.037∗	
	
Tonsillar swelling or exudate	Yes	14 (6.6)	76 (35.7)	2.65 (1.060–6.616)	0.032∗	3.83 (1.446–10.188)	0.007∗	
No	8 (3.8)	115 (54.0)	1	 	 	 	
	
Cough	Yes	14 (6.6)	100 (46.9)	1.59 (0.639–3.972)	0.315	—	—	
No	8 (3.8)	91 (42.7)	1	 	—	—	
	
Fever	>3 days	13 (6.1)	92 (43.2)	1.55 (0.634–3.808)	0.332	—	—	
≤3 days	9 (4.2)	99 (46.5)	1	 	—	—	
	
Headache	Yes	6 (2.8)	48 (22.5)	1	 	—	—	
No	16 (7.5)	143 (67.1)	1.12 (0.414–3.017)	0.827	—	—	
	
Nasal flow	Yes	15 (7.0)	91 (42.7)	2.36 (0.919–6.034)	0.068∗	0.41 (0.145–1.129)	0.084	
No	7 (3.3)	100 (46.9)	1	 	1	 	
	
Abdominal pain	Yes	4 (1.9)	51 (23.9)	1	 	—	—	
No	18 (8.5)	140 (65.7)	0.61 (0.197–1.888)	0.387	—	—	
	
Vomiting	Yes	11 (5.2)	128 (60.1)	0.49 (0.202–1.197)	0.112∗	1.43 (0.513–3.995)	0.493	
No	11 (5.2)	63 (29.6)	1	 	1	 	
OR: odds ratio, CI: confidence interval. Note. ∗Indicates the significant relation between variables, P value <0.05.
==== Refs
1 Balla M. M. Mergani A. Medani M. E. A. Abakar A. D. Molecular identification of Streptococcus pyogenes in isolates from children with pharyngitis, Gezira state, Sudan 2022 Advances in Microbiology 2022 12 8 500 510
2 Meletis G. Ketikidis A. L. S. Floropoulou N. Antimicrobial resistance rates of Streptococcus pyogenes in a Greek tertiary care hospital: 6-year data and literature review New Microbiologica 2023 46 1 37 42 36853816
3 Sun L. Xiao Y. Huang W. Prevalence and identification of antibiotic-resistant scarlet fever group A Streptococcus strains in some paediatric cases at Shenzhen, China Journal of Global Antimicrobial Resistance 2022 30 199 204 10.1016/j.jgar.2022.05.012 35618209
4 Tsai W.-C. Shen C.-F. Lin Y.-L. Emergence of macrolide-resistant Streptococcus pyogenes emm12 in southern Taiwan from 2000 to 2019 Journal of Microbiology, Immunology, and Infection 2021 54 6 1086 1093 10.1016/j.jmii.2020.08.019
5 Helal Z. M. Rizk D. E. Adel El-Sokkary M. M. Hassan R. Prevalence and characterization of Streptococcus pyogenes clinical isolates from different hospitals and clinics in Mansoura International Journal of Microbiology 2020 2020 11 5814945 10.1155/2020/5814945
6 Miller K. M. Carapetis J. R. Van Beneden C. A. The global burden of sore throat and group A Streptococcus pharyngitis: A systematic review and meta-analysis EClinicalMedicine 2022 48 101458 10.1016/j.eclinm.2022.101458
7 Barth D. D. Moloi A. Mayosi B. M. Engel M. E. Prevalence of group A Streptococcal infection in Africa to inform GAS vaccines for rheumatic heart disease: A systematic review and meta-analysis International Journal of Cardiology 2020 307 200 208 10.1016/j.ijcard.2019.11.109 31864789
8 Nayiga I. Okello E. Lwabi P. Ndeezi G. Prevalence of group a streptococcus pharyngeal carriage and clinical manifestations in school children aged 5–15 yrs in Wakiso District, Uganda BMC Infectious Diseases 2017 17 1 248 12875 10.1186/s12879-017-2353-5 2-s2.0-85017154279 28381239
9 Chillo P. Wangilisasi S. Kimambo D. Janabi M. Kamuhabwa A. Throat colonization and antibiotic susceptibility of group A β-hemolytic streptococci among rheumatic heart disease patients attending a cardiac referral hospital in Tanzania, A descriptive cross-sectional study Frontiers in Surgery 2019 7
10 Barth D. D. Daw J. Xu R. Modes of transmission and attack rates of group A Streptococcal infection: A protocol for a systematic review and meta-analysis Systematic Reviews 2021 10 90 97 10.1186/s13643-021-01641-5 33789732
11 Shobha K. L. Kusumakshi P. V. Ramachandra: Group A, G and C β-hemolytic streptococci India International Journal of Medicine 2015 3 1
12 Berbel D. González-Díaz A. López de Egea G. Càmara J. Ardanuy C. An overview of macrolide resistance in streptococci: Prevalence, mobile elements and dynamics Microorganisms 2022 10 12 p. 2316 10.3390/microorganisms10122316
13 Chazan B. Raz R. Edelstein H. Kennes Y. Gal V. Colodner R. Susceptibility of group A streptococcus to antimicrobial agents in northern Israel: A surveillance study Microbial Drug Resistance 2015 21 5 551 555 10.1089/mdr.2015.0040 2-s2.0-84943266880 26430943
14 Li H. Zhou L. Zhao Y. Ma L. Liu X. Hu J. J. B. I. D. Molecular epidemiology and antimicrobial resistance of group a streptococcus recovered from patients in Beijing, China BMC Infectious Diseases 2020 20 1 507 509 10.1186/s12879-020-05241-x 32660436
15 Kim M. L. Martin W. J. Minigo G. Dysregulated IL-1β-GM-CSF Axis in acute rheumatic fever that is limited by hydroxychloroquine Circulation 2018 138 23 2648 2661 10.1161/circulationaha.118.033891 2-s2.0-85058923652 30571257
16 Tyrrell G. J. Bell C. Bill L. Fathima S. Increasing incidence of invasive group A Streptococcus disease in first nations population, Alberta, Canada, 2003–2017 Emerging Infectious Diseases 2021 27 2 443 451 10.3201/eid2702.201945 33496247
17 Anja A. Beyene G. S/Mariam Z. Daka D. Asymptomatic pharyngeal carriage rate of Streptococcus pyogenes, its associated factors and antibiotic susceptibility pattern among school children in Hawassa town, southern Ethiopia BMC Research Notes 2019 12 1 p. 564 10.1186/s13104-019-4601-9 2-s2.0-85071980725 31500654
18 Kebede D. Admas A. Mekonnen D. Prevalence and antibiotics susceptibility profiles of Streptococcus pyogenes among pediatric patients with acute pharyngitis at Felege Hiwot Comprehensive Specialized Hospital, Northwest Ethiopia BMC Microbiology 2021 21 1 135 210 10.1186/s12866-021-02196-0 33941090
19 Tesfaw G. Kibru G. Mekonnen D. Abdissa A. Nose T. Prevalence of group A β-haemolytic Streptococcus among children with pharyngitis in Jimma town, Southwest Ethiopia Egyptian Journal of Ear, Nose, Throat and Allied Sciences 2015 16 1 35 40 10.1016/j.ejenta.2015.02.001 2-s2.0-84942077336
20 Tadesse M. Hailu Y. Biset S. Ferede G. Gelaw B. Prevalence, antibiotic susceptibility profile and associated factors of group A Streptococcal pharyngitis among pediatric patients with acute pharyngitis in Gondar, Northwest Ethiopia Infection and Drug Resistance 2023 16 1637 1648 10.2147/idr.s402292 36992964
21 Shamsuzzaman S. Multidrug-resistant, Extensively drug-resistant and Pandrug-resistant bacteria and antimicrobial therapy in combination Bangladesh Journal of Medical Microbiology 2017 9 2 1 2 10.3329/bjmm.v9i2.31348
22 Mwaba C. Nakazwe R. Mpabalwani E. Lukwesa-Musyani C. Mwansa J. Chipeta J. Chipeta: prevalence and antibiotic susceptibility of group A beta-haemolytic streptococcal isolates in children presenting with acute pharyngitis in Lusaka, Zambia South African Journal of Child Health 2020 14 2 99 103 10.7196/sajch.2020.v14i2.01684
23 Public Health England: UK Standards for Microbiology Investigations Identification of Streptococcus species Enterococcus species and morphologically similar organisms 2021 4 1 31 https://wwwrcpathorg/static/ce35b1b6-9d79-4125-a0f64ba28e9a3584/UK-SMI-ID-4i4-Identification-of-Streptococcus-species-Enterococcus-species-and-morphologically-similar-organisms-September-2021pdf
24 Institute CaLS: Clinical and laboratory standards institute (CLSI) Performance Standards for Antimicrobial Susceptibility Testing 2021 39 29th 2 Wayne, PA, USA CLSI 1 320
25 Malino I. Y. Utama D. L. Soenarto Y. McIsaac criteria for diagnosis of acute group-A Î2-hemolytic streptococcal pharyngitis Paediatrica Indonesiana 2016 53 5 258 263 10.14238/pi53.5.2013.258-63
26 Greer R. Althaus T. Ling C. Prevalence of group A Streptococcus in primary care patients and the utility of c-reactive protein and clinical scores for its identification in Thailand The American Journal of Tropical Medicine and Hygiene 2020 102 2 377 383 10.4269/ajtmh.19-0502 31889507
27 Khandekar A. Dangre-Mudey G. Tackling rheumatic heart disease: Prevalence and antibiogram of Streptococcus pyogenes in cases of paediatric pharyngitis Journal of Clinical and Diagnostic Research 2019 13 2 10.7860/jcdr/2019/38486.12626
28 Ughasoro M. D. Akpeh J. O. Echendu N. The profile of microorganisms that associate with acute tonsillitis in children and their antibiotics sensitivity pattern in Nigeria Scientific Reports 2021 11 1 20084 20089 10.1038/s41598-021-99570-9 34635755
29 Sayyahfar S. Fahimzad A. Naddaf A. Tavassoli S. Antibiotic susceptibility evaluation of group A streptococcus isolated from children with pharyngitis: A study from Iran Infection chemotherapy 2015 47 4 225 230 10.3947/ic.2015.47.4.225 2-s2.0-84957645228 26788405
30 Igarashi H. Nago N. Kiyokawa H. Fukushi M. Abdominal pain and nausea in the diagnosis of streptococcal pharyngitis in boys International Journal of General Medicine 2017 10 311 318 10.2147/ijgm.s144310 2-s2.0-85034111424 28989283
31 Ia Ba-Saddik A. M. Alhilali A. M. Ismail S. M. CM Parry Prevalence of Group A beta-haemolytic Streptococcus isolated from children with acute pharyngotonsillitis in Aden Yemen Tropical Medicine and International Health 2014 10 4 431 439
32 Kennis M. Tagawa A. Kung V. M. Seasonal variations and risk factors of Streptococcus pyogenes infection: A multicenter research network study Therapeutic Advances in Infectious Disease 2022 9 10.1177/20499361221132101 20499361221132101
33 Alves-Barroco C. Rivas-García L. Fernandes A. R. Baptista P. V. Tackling multidrug resistance in streptococci–from novel biotherapeutic strategies to nanomedicines Frontiers in Microbiology 2020 11 10.3389/fmicb.2020.579916 579916
34 Lin M.-H. Chang P.-F. Fong W.-K. Yen C.-W. Hung K.-L. Lin S.-J. Epidemiological and clinical features of group A Streptococcus pharyngitis in children Acta Paediatrica Taiwanica 2003 44 5 274 278 14964982
35 Liu Y. Chan T.-C. Yap L.-W. Resurgence of scarlet fever in China: A 13-year population-based surveillance study The Lancet Infectious Diseases 2018 18 8 903 912 10.1016/s1473-3099(18)30231-7 2-s2.0-85048430164 29858148
36 Lee C. F. Cowling B. J. Lau E. H. Epidemiology of reemerging scarlet fever, Hong Kong, 2005–2015 Emerging Infectious Diseases 2017 23 10 1707 1710 10.3201/eid2310.161456 2-s2.0-85029759231 28930009
37 Avire N. J. Whiley H. Ross K. A review of Streptococcus pyogenes: Public health risk factors, prevention and control Pathogens 2021 10 2 p. 248 10.3390/pathogens10020248
38 Engelthaler D. M. Valentine M. Bowers J. Hypervirulent emm59 clone in invasive group A Streptococcus outbreak, southwestern United States Emerging Infectious Diseases 2016 22 4 734 738 10.3201/eid2204.151582 2-s2.0-84961209531 26982330
39 Gay L. Melenotte C. Lakbar I. Sexual dimorphism and gender in infectious diseases Frontiers in Immunology 2021 12 10.3389/fimmu.2021.698121 698121
40 Nadeau N. L. Fine A. M. Kimia A. Improving the prediction of streptococcal pharyngitis; time to move past exudate alone The American Journal of Emergency Medicine 2021 45 196 201 10.1016/j.ajem.2020.08.023 33041117
41 Mahony T. Sidell D. Gans H. Palatal petechiae in the absence of group a streptococcus in pediatric patients with acute-onset neuropsychiatric deterioration: A cohort study Journal of Child and Adolescent Psychopharmacology 2017 27 7 660 666 10.1089/cap.2016.0153 2-s2.0-85042845317 28387528
42 Sauve L. Forrester A. M. Top K. A. Group A streptococcal pharyngitis: A practical guide to diagnosis and treatment Paediatrics and Child Health 2021 26 5 p. 319 10.1093/pch/pxab025
43 Prevantation CfDCa: Pharyngitis (strep throat) 2023 https://wwwcdcgov/groupastrep/diseases-hcp/strep-throathtml
